 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today...

Galecto Announces Plans to Explore Strategic Alternatives

Galecto, Inc. (NASDAQ:GLTO  Get Free Report) has earned a consensus rating of Moderate Buy from the seven analysts that are covering the stock, Marketbeat Ratings reports. Three...

Galecto, Inc. (NASDAQ:GLTO) Receives $7.60 Consensus Price Target from Analysts

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President and Chief Executive ...

Galecto to Present at Investor Conferences in September

Galecto (NASDAQ:GLTO  Free Report) had its price objective lowered by HC Wainwright from $12.00 to $2.00 in a research report report published on Monday, MarketBeat reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Galectos Q3 2023 ...

HC Wainwright Cuts Galecto (NASDAQ:GLTO) Price Target to $2.00

Galecto, Inc. (NASDAQ:GLTO  Free Report)  Stock analysts at HC Wainwright boosted their Q3 2023 earnings per share (EPS) estimates for shares of Galecto in a note issued to investors on Monday, August 21st. HC Wainwright analyst B. Pachaiyappan now anticipates that the company will ...

HC Wainwright Analysts Boost Earnings Estimates for Galecto, Inc. (NASDAQ:GLTO)

Galecto (NASDAQ:GLTO  Get Free Report) had its price objective decreased by equities researchers at HC Wainwright from $12.00 to $2.00 in a research report issued to clients and investors on Monday, MarketBeat reports. The firm presently has a buy rating on the stock. HC ...

Galecto (NASDAQ:GLTO) Price Target Cut to $2.00 by Analysts at HC Wainwright

Galecto, Inc. (NASDAQ:GLTO  Free Report)  Research analysts at Cantor Fitzgerald lifted their FY2023 EPS estimates for shares of Galecto in a report issued on Thursday, August 17th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will earn ($1.34) per share for the ...

Cantor Fitzgerald Weighs in on Galecto, Inc.'s FY2023 Earnings (NASDAQ:GLTO)

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Galecto (GLTO Research Report), Amylyx Pharmaceuti... Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Galecto (GLTO Research Report), Amylyx ...

Analysts Are Bullish on Top Healthcare Stocks: Galecto (GLTO), Amylyx Pharmaceuticals Inc (AMLX)

SVB Leerink reiterated their market perform rating on shares of Galecto (NASDAQ:GLTO  Free Report) in a research report released on Tuesday , Benzinga reports. They currently have a $2.00 price target on the stock, down from their prior price target of $13.00. A number of other equities ...

SVB Leerink Reaffirms Market Perform Rating for Galecto (NASDAQ:GLTO)

SVB Securities cut shares of Galecto (NASDAQ:GLTO  Free Report) from an outperform rating to a market perform rating in a research report sent to investors on Tuesday, FlyOnTheWall reports. Several other equities analysts have also recently weighed in on the company. SVB Leerink restated a ...

Galecto (NASDAQ:GLTO) Lowered to "Market Perform" at SVB Securities

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Watchers	2,892
52-Wk Low	$0.50
52-Wk High	$3.70

Market Cap	$16.89M
Volume (M)	259,494.00
52-Wk High	$3.70
52-Wk Low	$0.50

GLTO Galecto Inc

About

Feed

News

Sentiment

Earnings

Fundamentals